VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 94 filers reported holding VERONA PHARMA PLC in Q1 2023. The put-call ratio across all filers is 1.24 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $213,767 | -2.5% | 318,591 | +1.6% | 0.03% | -25.7% |
| Q2 2023 | $219,207 | -95.2% | 313,677 | +37.2% | 0.04% | -96.6% |
| Q1 2023 | $4,591,834 | -61.4% | 228,677 | -49.8% | 1.04% | -63.7% |
| Q4 2022 | $11,892,573 | +6062.0% | 455,131 | +44.4% | 2.87% | +7450.0% |
| Q3 2022 | $193,000 | -3.5% | 315,131 | +5.0% | 0.04% | +5.6% |
| Q2 2022 | $200,000 | – | 300,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |